The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1523
June 19, 2017
View Complete Issue         Table of Contents 2019 
Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus
June 19, 2017 (Issue: 1523)
The FDA has approved the ophthalmic solutions riboflavin 5'-phosphate in 20% dextran (Photrexa Viscous – Avedro) and riboflavin 5'-phosphate alone (Photrexa) for use with ultraviolet A (UVA) light (KXL System) in the corneal collagen...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus
Article code: 1523e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.